AVGO vs RXRX Stock Comparison
Compare AVGO and RXRX across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between AVGO and RXRX?
AVGO leads the current stock comparison as Broadcom Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Broadcom Inc. vs Recursion Pharmaceuticals, Inc.
AVGO leads
AVGO leads by 15 AIQ points, primarily on Quality, and the lead has widened from 0 points over 30 sessions. Wall Street currently favors RXRX on target upside.
Competitive: 3 of 6 evidence groups support AVGO, its lead is widening, and its current signal state is conflicted.
Broadcom Inc.
Recursion Pharmaceuticals, Inc.
The Algovestiq AIQ Score currently favors AVGO over RXRX, 52 versus 37 as of Sep 11, 2026. AVGO's advantage is driven primarily by stronger quality, while RXRX holds the stronger risk resilience profile. AVGO also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors RXRX. 3 of 6 covered evidence groups favor AVGO today, and the comparison is rated Competitive on stability: only 3 of 6 covered evidence groups agree. AVGO lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions.
Compare Broadcom Inc. and Recursion Pharmaceuticals, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare AVGO and RXRX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality85 vs 29AVGO +56
- Risk Resilience52 vs 58RXRX +6
- Value30 vs 34RXRX +4
- Momentum39 vs 38Even
3 of 6 evidence groups favor AVGO. AVGO’s edge is concentrated in quality; RXRX keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -3
No new signals fired.
Largest factor move: Momentum +2
No new signals fired.
AVGO's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — AVGO and RXRX both carry a full feed there.
The central trade-off
AVGO (Broadcom Inc.): the stronger current systematic profile, led by quality.
RXRX (Recursion Pharmaceuticals, Inc.): the counter-case, on risk resilience, value, valuation — but at materially higher volatility, 82.8% against 37.6%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
AVGOAVGO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
AVGOAVGO on combined revenue and EPS growth.
Value
RXRXRXRX on the peer-relative Value factor, by 4 points.
Momentum
EvenThe two are level on Momentum.
Lower downside
RXRXRXRX on Risk Resilience, by 6 points.
Analyst upside
RXRXRXRX on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors AVGO, analyst targets favor RXRX. That disagreement is the most useful thing on this page.
| Measure | AVGO | RXRX | Note |
|---|---|---|---|
| Implied upside to target | +39.4% | +68.8% | RXRX has more room |
| Target dispersion | +49.5% | +3.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 17 | 1 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor AVGO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | AVGO | 52 vs 37 |
| Fundamentals | AVGOon balance | revenue growth 14.9% vs 18.5%; EPS growth 26.5% vs -13.6%; TTM ROE 36.4% vs -50.4%; gross margin 67% vs -46.7%; operating margin 43.7% vs -9.9% — AVGO takes 4 of 5 decided legs, not all of them |
| Valuation | RXRX | Value 30 vs 34 |
| Technicals | AVGO | Price vs 50-day -5.5% vs -3.2%; vs 200-day -2.5% vs -13.1% |
| Risk Resilience | RXRX | Risk Resilience 52 vs 58 |
| Analyst expectations | RXRX | Target upside 39.4% vs 68.8% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of AVGO and RXRX and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 15 points. (supports the conclusion holding)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on AVGO.
How the comparison changed
119 daily snapshots · May 4 – Sep 10AVGO lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions.
- Today
- AVGO +15
- 52 vs 37
- 7 sessions ago
- AVGO +3
- 47 vs 44
- 30 sessions ago
- Level
- 45 vs 45
- 90 sessions ago
- AVGO +4
- 50 vs 46
The lead changed hands once in this window, most recently on Aug 25 when RXRX moved ahead of AVGO.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (3.55%)
- MACD Bearish Crossover — bearish, momentum, short horizon
0 bullish / 3 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (9.97%)
- Downtrend Structure Active — bearish, trend, long horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.16%)
AVGO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.32%, AIQ -1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.27%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1RXRX closes the Quality gap — currently 56 points behind, the largest single contributor to AVGO's edge.
- 2RXRX's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3AVGO's conflicting signal state resolves bearish — it currently carries 1 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
AVGO leads on balance| Metric | AVGO | RXRX |
|---|---|---|
| Revenue growth (YoY) | 14.9% | 18.5% |
| EPS growth (YoY) | 26.5% | -13.6% |
| Gross margin | 67% | -46.7% |
| Operating margin | 43.7% | -9.9% |
| Return on equity (TTM) | 36.4% | -50.4% |
| Debt to equity | 0.74 | 0.07 |
Performance
AVGO leads 4 of 6 windows| Metric | AVGO | RXRX |
|---|---|---|
| 1 week (5 sessions) | -1.7% | -6.5% |
| 1 month (20 sessions) | -13.3% | -4% |
| 3 months (63 sessions) | -3% | 3.9% |
| 6 months (126 sessions) | 5.6% | -8.4% |
| Year to date | 4.3% | -22.7% |
| 1 year (252 sessions) | 6.9% | -31.6% |
Technicals
AVGO has the stronger structure| Metric | AVGO | RXRX |
|---|---|---|
| RSI (14) | 47.7 | 45.1 |
| ADX (14) | 23.4 | 12.8 |
| Price vs 50-day | -5.5% | -3.2% |
| Price vs 200-day | -2.5% | -13.1% |
| Volatility (1M, annualized) | 37.6% | 82.8% |
Risk
RXRX is the more resilient| Metric | AVGO | RXRX |
|---|---|---|
| Beta | 2.16 | 2.88 |
| Sharpe ratio | 0.3 | -0.26 |
| Sortino ratio | 0.44 | -0.5 |
| Max drawdown | -28.9% | -58.2% |
| Current drawdown | -25.1% | -53.5% |
| Annualized volatility | 47.5% | 71.8% |
| Value at risk (95%) | -4.4% | -6.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, AVGO or RXRX?
On the Algovestiq AIQ Score, AVGO is the stronger of the two as of Sep 11, 2026, scoring 52 against RXRX's 37. The edge comes from quality. RXRX is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is AVGO or RXRX the better buy right now?
AVGO carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 3 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor AVGO over RXRX?
The composite weights Quality, Value, Momentum and Risk Resilience. AVGO leads Quality by 56 points; RXRX leads Risk Resilience by 6 points; RXRX leads Value by 4 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, AVGO or RXRX?
Analyst price targets imply +39.4% upside for AVGO and +68.8% for RXRX, so the Street currently favors RXRX. That points the opposite way to the AIQ Score, which favors AVGO. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, AVGO or RXRX?
RXRX is the better-valued of the two on the peer-relative Value factor. RXRX on the peer-relative Value factor, by 4 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, AVGO or RXRX?
AVGO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, AVGO or RXRX?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, AVGO or RXRX?
RXRX is the more resilient of the two, so the other name carries the higher downside risk. RXRX on Risk Resilience, by 6 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is AVGO more profitable than RXRX?
AVGO leads on the comparable margin measures — gross margin 67% vs -46.7%; operating margin 43.7% vs -9.9%; ttm roe 36.4% vs -50.4%.
Is AVGO's lead over RXRX getting stronger or weaker?
AVGO lead: Strengthening — the AIQ differential moved from 0 to 15 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands once in that window, most recently on 2026-08-25, when RXRX moved ahead of AVGO.
What would change the AVGO vs RXRX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: RXRX closes the Quality gap — currently 56 points behind, the largest single contributor to AVGO's edge; RXRX's Death Cross Active resolves — a bearish trend rule currently active against it; AVGO's conflicting signal state resolves bearish — it currently carries 1 bullish and 1 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about AVGO and RXRX?
AVGO: 1 bullish / 1 bearish, conflicted. RXRX: 0 bullish / 3 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on AVGO is Golden Cross Active (bullish, long horizon). On RXRX it is Death Cross Active (bearish, long horizon).
Compare AVGO and RXRX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.